Haemonetics (NYSE:HAE) Price Target Lowered to $62.00 at JPMorgan Chase & Co.

Key Points

• JPMorgan Chase & Co. lowered its price target on Haemonetics to $62 from $74 and kept a neutral rating, implying about 12.5% upside from the current share price.
• Other analysts remain mixed-to-bullish overall: the stock has a Moderate Buy consensus with an average target price of $79.89, though several firms have recently trimmed their targets.
• Haemonetics recently beat quarterly earnings and revenue estimates, reporting $1.29 EPS on $346.35 million in revenue, with sales up 4.8% year over year.

Haemonetics (NYSE:HAE - Get Free Report) had its price objective lowered by stock analysts at JPMorgan Chase & Co. from $74.00 to $62.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a "neutral" rating on the medical instruments supplier's stock. JPMorgan Chase & Co.'s price objective would suggest a potential upside of 12.47% from the stock's current price.

Several other research firms have also recently weighed in on HAE. Robert W. Baird set a $67.00 price objective on shares of Haemonetics in a research report on Friday. Mizuho cut their price objective on shares of Haemonetics from $80.00 to $70.00 and set an "outperform" rating for the company in a research report on Monday, April 13th. Citigroup cut their price objective on shares of Haemonetics from $75.00 to $70.00 and set a "neutral" rating for the company in a research report on Wednesday, March 11th. Wall Street Zen raised shares of Haemonetics from a "hold" rating to a "buy" rating in a research report on Saturday, January 10th. Finally, BTIG Research reaffirmed a "buy" rating and set a $88.00 price objective on shares of Haemonetics in a research report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Haemonetics has an average rating of "Moderate Buy" and an average target price of $79.89.

Haemonetics Stock Performance

Shares of HAE stock traded up $0.76 on Friday, hitting $55.13. The company's stock had a trading volume of 647,875 shares, compared to its average volume of 827,052. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.15 and a current ratio of 1.75. The stock's 50 day moving average is $59.53 and its 200-day moving average is $66.68. Haemonetics has a fifty-two week low of $47.31 and a fifty-two week high of $87.32. The company has a market capitalization of $2.56 billion, a PE ratio of 15.19, a PEG ratio of 1.03 and a beta of 0.53.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, beating the consensus estimate of $1.28 by $0.01. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The business had revenue of $346.35 million for the quarter, compared to the consensus estimate of $336.83 million. During the same period in the prior year, the company posted $1.24 earnings per share. Haemonetics's revenue was up 4.8% compared to the same quarter last year. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Equities research analysts expect that Haemonetics will post 4.95 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in HAE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Haemonetics by 3.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier's stock worth $1,877,000 after acquiring an additional 971 shares during the last quarter. Caxton Associates LLP bought a new position in shares of Haemonetics in the first quarter worth about $216,000. United Services Automobile Association acquired a new position in shares of Haemonetics in the first quarter valued at approximately $212,000. Empowered Funds LLC increased its stake in shares of Haemonetics by 9.1% in the first quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier's stock valued at $283,000 after buying an additional 372 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Haemonetics by 6.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier's stock valued at $9,923,000 after buying an additional 9,051 shares during the period. Institutional investors own 99.67% of the company's stock.

More Haemonetics News

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Q4 results beat consensus: Haemonetics reported $1.29 EPS and $346.4M revenue (both ahead of Street estimates), with revenue up ~4.8% year-over-year — a core reason investors are bidding the stock up. Haemonetics NYSE: HAE Reports Upbeat Q1 CY2026
• Positive Sentiment: Management expects FY2027 revenue growth of 4%–7%, citing continued Persona PLUS rollout and efforts to rebound IVT volumes — these operational drivers support the growth narrative that investors are rewarding. Haemonetics projects FY 2027 revenue growth of 4% to 7%...
• Positive Sentiment: Outside buying signal: The London Company’s Small Cap Portfolio added to Haemonetics following recent volatility, indicating some institutional interest that can lift sentiment and trading. The London Company Small Cap Portfolio Q1 2026 Portfolio Review
• Neutral Sentiment: FY2027 EPS guidance band (5.258–5.307) is roughly in line with consensus (about 5.29), so while guidance supports stability, it doesn’t represent a clear upside surprise versus expectations. PR Newswire: Financial results available
• Neutral Sentiment: Investors can review the full earnings call transcript and supplemental materials for management commentary and cadence on Persona PLUS and IVT recovery; these details will shape whether the current upbeat reaction sustains. Haemonetics Q4 2026 Earnings Call Transcript

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company's offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company's product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.